{"classes":[{"categories":[{"measurements":[{"comment":"insufficient number of participants with events","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"126"}],"units":"Participants"}],"description":"Overall survival, defined as the time from start date of TFR (date of entering the TFR phase) to date of death due to any cause at any time during the study, including the follow-up period after discontinuation of study up to LPLV. If a patient is not known to have died, survival will be censored at the date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"TFR is defined as no confirmed loss of MR4 (Molecular response 4.0 log reduction from baseline) or loss of MMR (major molecular response) and no re-starting of nilotinib therapy within 12 months following cessation of nilotinib. Confirmed loss of MR4 is two consecutive BCR-ABL \\> 0.01% IS. Loss of MMR does not require confirmation.","id":"OG000","title":"TFS Phase"}],"paramType":"MEDIAN","populationDescription":"Full analysis set (FAS) included all patients who completed the consolidation phase successfully and entered the TFR phase.","reportingStatus":"POSTED","timeFrame":"nilotinib cessation up to approximately 580 weeks","title":"Overall Survival (OS) After the Start of the TFR Phase","type":"SECONDARY","unitOfMeasure":"Weeks"}